Efficacy and tolerability of two oral hyoscine butylbromide formulations in Chinese patients with recurrent episodes of self-reported gastric or intestinal spasm-like pain

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 3, 2011, Pages 198-205

  Ge, Z ^a   Yuan, Y ^b   Zhang, S ^c   Hou, X ^d   Wang, J ^e   Cai, J ^f   Shi, R ^g   Li, Y ^h   Wang, B ⁱ   Ji, F ^f   Richter, E ^j   Schaefer, E ^j  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e FUDAN UNIVERSITY   (China)

^f ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g NANJING MEDICAL UNIVERSITY   (China)

^h SHANDONG UNIVERSITY   (China)

ⁱ TIANJIN MEDICAL UNIVERSITY   (China)

^j BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

more..

Author keywords

Abdominal cramps; Abdominal pain; Antispasmodic agents; Functional colonic diseases; Hyoscine butylbromide

Indexed keywords

PLACEBO; SCOPOLAMINE BUTYL BROMIDE;

ABDOMINAL PAIN; ADULT; AGED; ANALGESIC ACTIVITY; ARTICLE; CHINESE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL PAIN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PAIN PARAMETERS; PATIENT ATTITUDE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECURRENT DISEASE; SELF REPORT; TABLET; VISUAL ANALOG SCALE;

ABDOMINAL PAIN; ADMINISTRATION, ORAL; ADULT; AGED; BUTYLSCOPOLAMMONIUM BROMIDE; CAPSULES; CHINA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; SPASM; TABLETS; TIME FACTORS; YOUNG ADULT;

EID: 79952215758     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201485     Document Type: Article

References (21)

1. Bommelaer G, Poynard T, Le Pen C et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol Clin Biol. 2004; 28: 554-561. (Pubitemid 38917487)
2. Drossman DA, Richter JE, Talley NJ et al. The functional gastrointestinal disorders, pathophysiology and treatment - a multinational consensus. Boston: Little Brown and Co, 1994.
3. Evangelista S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des. 2004; 10: 3561-3568. (Pubitemid 39378335)
4. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008; 337: 1388-1392 & a2313. Erratum in: BMJ. 2009; 338: b1881.
5. Hu PJ. Consensus on the diagnosis and treatment of irritable bowel syndrome. Chin J Dig Dis. 2003; 4: 147-149. (Pubitemid 37483894)
6. Hungin APS, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 patients. Aliment Pharmacol Ther. 2003; 17: 643-650. (Pubitemid 36418887)
7. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomised, controlled trials. Ann Intern Med. 2000; 133: 136-147. (Pubitemid 30490414)
8. Manning AP, Thompson WG, Heaton KE, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J. 1978; 2: 653-654. (Pubitemid 9004104)
9. Mertz HR. Irritable bowel syndrome. N Eng J Med. 2003; 349: 2136-2146. (Pubitemid 37464539)
10. Mueller-Lissner S, Tytgat GN, Paulo LG, Quigley EMM, Bubeck J, Peil H, Schaefer E. Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. Aliment Pharmacol Ther. 2006; 23: 1741-1748. (Pubitemid 43846418)
11. Nigam P, Kapoor KK, Rastog CK, Kumar A, Gupta AK. Different therapeutic regimens in irritable bowel syndrome. J Assoc Physicians India. 1984; 32: 1041-1044.
12. Pomeroy AR, Rand MJ. Anticholinergic effects and passage through the intestinal wall of N-buthylhyoscine bromide. J Pharm Pharmacol. 1969; 21: 180-187.
13. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001; 15: 355-361. (Pubitemid 32187557)
14. Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome (review). Cochrane Database Syst Rev. 2005; 2: CD0033460.
15. Quigley EMM, Locke GR, Mueller-Lissner S, Paulo LG, Tytgat GN, Helfrich I, Schaefer E. Prevalence and management of abdominal cramping and pain: a multinational survey. Aliment Pharmacol Ther. 2006; 24: 411-419. (Pubitemid 43972910)
16. Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide and ispaghula husk. Br Med J. 1979; 1: 376-378. (Pubitemid 9095236)
17. Sandler RS, Stewart WF, Liberman JN, Ricci JA, Zorich NL. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. Dig Dis Sci. 2000; 45: 1166-1171. (Pubitemid 30409462)
18. Schaefer E, Ewe K. Treatment of irritable bowel syndrome: efficacy and tolerance of Buscopan plus, Buscopan, paracetamol and placebo in ambulatory patients with IBS. Fortschr Med. 1990; 108: 488-492.
19. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Mueller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999; 45: 43-47.
20. Tytgat GN. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs. 2007; 67: 1343-1357. (Pubitemid 46879098)
21. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut. 1999; 45: 69-77.